#USA #Annapolis #Atopic Dermatitis #Zabalafin Hydrogel #Alphyn Biologics

Alphyn Biologics Secures Innovative U.S. Patent for Atopic Dermatitis Treatment

Alphyn Biologics, Inc., a clinical-stage dermatology company, recently announced the granting of a significant new patent from the U.S. Patent and Trademark Office (USPTO). This newly awarded patent focuses on the active pharmaceutical ingredient (API) within its leading candidate for treating atopic dermatitis (AD), a common inflammatory skin condition. As stated by Alphyn's CEO, Neal Koller, this patent marks a pivotal moment for the company as it expands its intellectual property portfolio in dermatological therapeutics.

The new patent protects the topical application of its drug compound, which is expected to provide effective relief for individuals suffering from atopic dermatitis. Notably, this patent ensures protection until 2041 and complements an earlier patent for the Zabalafin Hydrogel products, which are expected to be protected until 2043. Both patents are set to be listed in the U.S. Food and Drug Administration's (FDA) Orange Book once FDA approval is granted, providing additional safeguards for these innovative therapeutic products.

Alphyn has been diligently working to grow its patent estate, securing several patents globally for its drugs and the Multi-Target Therapeutic Platform it has developed. In addition to the U.S. patent, the company recently received a Notice of Allowance from the European Patent Office for claims related to the Zabalafin Hydrogel, signaling a broader footprint in protecting its innovations across different markets.

About Zabalafin Hydrogel

The Zabalafin Hydrogel is positioned to be a breakthrough treatment for atopic dermatitis. Clinical trials have demonstrated its efficacy and safety, suggesting it could be the first treatment of its kind that allows for continuous use without safety concerns. This innovative hydrogel is designed to directly address various aspects of atopic dermatitis: it alleviates intense itching, targets bacterial elements associated with the condition, and combats the immunological and inflammatory responses that characterize AD.

What sets the Zabalafin Hydrogel apart from other treatments is its unique formulation containing multiple bioactive compounds. This allows the hydrogel to operate through various mechanisms of action, thereby providing a comprehensive solution to skin conditions that challenge patients with both efficacy and safety. With the promise of fewer side effects and better patient tolerability, this product could revolutionize the way atopic dermatitis is managed.

Background on Alphyn Biologics

Founded in 2020, Alphyn Biologics is rapidly establishing itself as a leader in dermatological treatments with a focus on severe skin diseases. Headquartered in Annapolis, Maryland, with a subsidiary in Cincinnati, Ohio, the company has successfully raised approximately $21 million to fund its research and development endeavors. Their innovative approach employs advanced therapeutic platforms designed to deliver superior care for patients suffering from chronic skin conditions.

Alphyn Biologics is committed to advancing dermatology by leveraging its expertise, and the latest patent granting is testimony to its successful journey in perfecting novel therapies. With atopic dermatitis affecting millions worldwide, the need for effective and safe treatments is more crucial than ever. The Zabalafin Hydrogel and its growing patent estate position Alphyn as a disruptive force in addressing these persistent dermatologic challenges.

In conclusion, with strong leadership and a visionary approach, Alphyn Biologics is well on its way to making a significant impact on the management of atopic dermatitis, ensuring that patients have access to groundbreaking treatments that can improve their quality of life.